Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT05151523

Long-term Recurrence Rates of Atrial Fibrillation Following New-onset Atrial Fibrillation During ICU Admission

The Primary Objective of the study is to establish the One-year recurrence rates of atrial fibrillation (AF) following new-onset atrial fibrillation during intensive care unit (ICU) admission.

The Secondary Objective is a composite of death from cardiovascular causes, stroke (either ischemic or hemorrhagic), or hospitalization with worsening of heart failure or recurrent AF.

The prevalence and recurrence rates of AF will be divided into sub-groups based on primary ICU admission diagnosis.

All-cause mortality.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

About this study

Patients will be screened for atrial fibrillation during hospitalization in the intensive care unit and will be followed until discharge. Once discharged home or to a rehabilitation center, they will be invited to a routine follow-up clinic at RMC cardiology institute 4-6 weeks after hospital discharge. During the clinic visit, patients will be recruited to the study follow-up plan.

The follow-up plan will consist of 3 clinical visits at 4-6 weeks, 6-months and 1 -year after discharge.

The follow-up program will include a comprehensive screening for symptomatic and asymptomatic atrial fibrillation events as following:

Patients will be provided with a home cellular-digital 12-lead ECG transmitter. They will be instructed to conduct routine weekly transmission in order to record asymptomatic events as well as to transmit at any time they suspect an event/feel symptoms (palpitations). Home routine testing will be initiated and guided by a telephone call from a medical monitoring center. A blinded, independent, on-call medical professional team will analyze the received ECG.

A 48-hour Holter ECG will be performed at 6 months and 12 months after ICU discharge

Clinical visits will include 12 leads ECG, physical examination, vital signs, symptoms evaluation for suspected AF events, questioning for hospital admissions, or any other documented AF event. Patients will be asked to perform echocardiography as part of their clinical evaluation. For both the study and control group, documented AF events will be managed according to physician discretion based on clinical practice and guidelines.

Long-term follow-up- 3 years- data regarding recurrent events of AF, hospitalization due to thromboembolic events, and mortality will be evaluated by telephone call or by matching patient identification numbers with the Israeli National Population Register.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Admitted to ICU over 24 hours
  • Diagnosed with new-onset atrial fibrillation
  • The patient survived the index hospitalization and was discharged home/ to a rehabilitation center.

Exclusion criteria

  • Previously documented atrial fibrillation

Treatment and study plan

Primary outcomes

  1. Recurrence rates of atrial-fibrillation following new-onset atrial-fibrillation during intensive care unit

    Time frame: One-year

    A positive ECG or Holter test for atrial fibrillation will be regarded as recurrence.

Secondary outcomes

  1. Major adverse cardiovascular events

    Time frame: 3-years

    A composite of death from cardiovascular causes, stroke (either ischemic or hemorrhagic), or hospitalization with worsening of heart failure or recurrent AF.

  2. Recurrence rates of atrial-fibrillation

    Time frame: 3-years

    The prevalence and recurrence rates of atrial-fibrillation divided into sub-groups based on primary ICU admission diagnosis.

  3. All-cause mortality

    Time frame: 3-years

    All-cause mortality will be monitored on clinical flow-up.

Study contacts

Contact information is provided by the study sponsor or research team.

Katia Orvin, M.D

CONTACT

[email protected]

+972548001942

LIOR FISHER, M.D

CONTACT

[email protected]

+972547440708

Sponsors and collaborators

Lead sponsor

Katia Orvin

Other

Registry information

Important dates

Study start
2022
Primary completion
2025
Study completion
2026
First posted
Dec 9, 2021
Registry last updated
Dec 16, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.